Psychiatr. pro Praxi, 2009; 10(5): 216-219 [Neurol. praxi. 2009;10(1):28-31]

Treatment guidelines for Alzheimer‘s disease and other dementias

MUDr. Kateřina Sheardová1, doc. MUDr. Vladimír Hort CSc2, MUDr. Robert Rusina3, MUDr. Aleš Bartoš Ph.D4, MUDr. Vladimír Línek5, MUDr. Pavel Ressner, Ph.D6, doc. MUDr. Irena Rektorová, Ph.D1
1 I. neurologická klinika LF MU a FN u sv. Anny Brno
2 Dětská psychiatrická klinika 2. LF UK a FN v Motole, Praha
3 Neurologická klinika IPVZ, Fakultní Thomayerova nemocnice Praha
4 Neurologická klinika 3. LF UK a FN KV, Praha
5 Neurologická klinika 1. LF UK a VFN, Praha
6 Neurologické oddělení, Nemocnice s poliklinikou v Novém Jičíně

These guidelines have been developed to assist practical neurologists, geriatricians, psychiatrists, and other specialists involved in the care

of patients with dementia. The paper is grounded on scientifically based treatment procedures that are mainly based on double-blind,

placebo-controlled studies and meta-analyses. We present the guidelines for the treatment of Alzheimer‘s disease, vascular dementia,

Parkinson‘s disease with dementia, and dementia with Lewy bodies. These guidelines should result in rational and effective treatment

procedures in the most common types of dementia.

Keywords: dementia, Alzheimer‘s disease, treatment procedures, ACE inhibitors.

Published: November 1, 2009  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Sheardová K, Hort V, Rusina R, Bartoš A, Línek V, Ressner P, Rektorová I. Treatment guidelines for Alzheimer‘s disease and other dementias. Psychiatr. praxi. 2009;10(5):216-219.
Download citation

References

  1. Black S, Roman GC, Geldmacher DS, et al. Efficacy and tolerability of donepezil in vascular dementia: positive results of a 24-week, multicenter, international, randomized, placebo-controlled clinical trial. Stroke 2003; 34: 2323-2330. Go to original source... Go to PubMed...
  2. Emre M, Aarsland D, Albanese A, et al. Rivastigmine for dementia associated with Parkinson's disease. New England Journal of Medicine 2004; 351: 2509-2518. Go to original source... Go to PubMed...
  3. Feldman H, Gauthier S, Hecker J, et al. Donepezil MSAD Study Investigators Group. A 24-week, randomized, doubleblind study of donepezil in moderate to severe Alzheimer's disease. Neurology 2001; 57: 613-620. Go to original source... Go to PubMed...
  4. Forette F, Seux ML, Staessen JA, et al. The prevention of dementia with antihypertensive treatment: new evidence from the Systolic Hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; Oct 14; 162(18): 2046-2052. Go to original source... Go to PubMed...
  5. Mazza M, Capuano A, Bria P, et al. Ginkgo biloba and donepezil: a comparison in the treatment of Alzheimer´s dementia in a randomized placebo-controlled double-blind study. European Journal of Neurology 2006; 13: 981-985. Go to original source... Go to PubMed...
  6. Nice. Alzheimer's disease - donepezil, rivastigmine and galantamine. NICE Tehnology Appraisal Guidance - No 19. 2001 www.nice.org.uk (accessed February 24, 2006).
  7. Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: A 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000; 54: 2261-2268. Go to original source... Go to PubMed...
  8. Reisberg B, Doody R, Stoffler A, et al. Memantine Study Group. Memantine in moderate-to-severe Alzheimer's disease. New England Journal of Medicine 2003; 348: 1333-1341. Go to original source... Go to PubMed...
  9. Seltzer B, Zolnouni B, Nunez M, et al. Efficacy of donepezil in early-stage Alzheimer disease: a randomized placebocontrolled trial, Arch Neurol 2004. Go to original source...
  10. Sheardová K, Hort J, Rusina R, et al. Za Sekci kognitivní neurologie České neurologické společnosti ČLS JEP. Doporučené postupy pro léčbu Alzheimerovy nemoci a dalších onemocnění spojených s demencí, Čes. slov. neurol N. 2007; 70/103(5): 253-258.
  11. Small GW, Kaufer D, Mendiondo MS, et al. Cognitive performance in Alzheimer's disease patients receiving rivastigmine for up to 5 years. Int J Clin Pract 2005. Go to original source... Go to PubMed...
  12. Tariot PN, Farlow MR, Grossberg GT, et al. Memantine treatment in patients with moderate to severe Alzheimer disease already receiving donepezil: a randomized controlled trial. Journal of the American Medical Association 2004; 291: 317-324. Go to original source... Go to PubMed...
  13. Wilkinson D, Doody R, Helme R, et al. Donepezil in vascular dementia: a randomized, placebo-controlled study. Neurology 2003; 61: 479-486. Go to original source... Go to PubMed...




Psychiatry for Practice

Madam, Sir,
please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

I declare:

  1. that I have met the above instruction
  2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited


No

Yes

If your statement is not true, please be aware
that brings the risk of danger to their health or the health of others.